Q: In answering another question you indicated price appreciation was likely already baked in for MRNA however at 6x earnings, a huge cash position, people not willing to get vaccines and the probability of ongoing covid variants, is this stock not a screaming buy? Your analysis please.
Read AnswerQ: If one believes in the potential importance of mRNA therapies to the future of human medicine in applications beyond COVID vaccines, which company would stand to benefit the most? Which are likely to benefit the most in the short term from COVID vaccines, or is this "baked in" for most already? Deduct points as needed and thank you for your excellent service.
Read Answer
Q: Haven’t seen a question since January. MDRA looks over sold and the stock has just issued a possible early technical buy signal using scholastics. More importantly this mRNA technology got another “shot in the arm” with the latest data indicting that they may work by STOPPING transmission not just mounting an immune response to decrease the course f the disease while you remain contagious. How well funded is MRNA. How is their free cash flow and their debt load. This technology keeps getting more and more exciting. Malaria, the common cold, HIV, etc!! And if is better maybe even influenza?
For the science geeks: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
Aaron J Tande, MD, Benjamin D Pollock, PhD, MSPH, Nilay D Shah, PhD, Gianrico Farrugia, MD, Abinash Virk, MD, Melanie Swift, MD, MPH, Laura Breeher, MD, MPH, Matthew Binnicker, PhD, Elie F Berbari, MD Author Notes
Clinical Infectious Diseases, ciab229, https://doi.org/10.1093/cid/ciab229
Published: 10 March 2021